FREE REPORT: Secure Your Copy

Download Now

The Biotech Bull Market’s Best‑Kept Secret


Unlock the Overlooked Opportunity Created by the GLP-1 Weight-Loss Revolution

GLP-1 drugs created a second market. Most investors have no idea it exists…

Rapid weight loss is driving a measurable surge in demand for body restoration, skin tightening, and structural repair. Procedure volumes are already rising. Commercial programs are already underway. Conventional research is still catching up.

This Rebel Research Report examines the companies positioned to profit from this restorative aesthetics megatrend.

  • Large dermatology plays already building clinical programs
  • Device and injectables specialists riding the GLP-1 demand
  • One early-stage regenerative platform at the cutting edge of tissue support
Claim Your FREE Copy

Get instant access to the report!

The Biotech Bull Market's Best-Kept Secret - a Market Rebellion research report

By clicking “Download Now” you agree to receive marketing offers from Market Rebellion, and its affiliates, subsidiaries, or agents in the form of emails, pre-recorded messages, text messages, and autodialed calls at the email address and phone number provided above, even if the phone number is present on a state or national Do Not Call list. You recognize that you are not required to provide this consent as a condition of purchase and that you can withdraw consent at any time. Data rates may apply. By clicking below, you also agree to our Terms of Use and acknowledge our Privacy Policy.


The Aesthetics Aftermath of GLP-1 Drugs

Why this report matters right now.

The scale of post-GLP-1 aesthetic demand is already visible.

More than 837,000 patients have reported post-weight-loss changes linked to GLP-1 use. Roughly one in ten U.S. adults have taken a GLP-1 agent. Projected global sales of $126 billion by 2029 signal a sizable patient pool still to come.

Demand for solutions is no longer theoretical. Large dermatology companies are running clinical programs for volume loss. Device makers are citing skin-tightening demand on earnings calls. Regenerative platforms are advancing technologies built for structural restoration.

This is not another overview of the primary weight-loss drug market…

It’s a focused Market Rebellion research report revealing the restorative aesthetics market those drugs have created—and the companies already positioned to serve it.

Download Now

Get Instant Access to the FREE Report

Actionable ideas you can use for your own portfolio.

The Biotech Bull Market’s Best-Kept Secret

  1. Chapter 1

    What “Ozempic Face” Represents Clinically

    Volume loss, skin laxity, and accelerated aging appearance after rapid fat reduction; distinction from traditional post-bariatric presentations.

  2. Chapter 2

    Sizing the Downstream Opportunity

    Procedure statistics, survey data on aesthetic-transformer users, and the relationship between projected GLP-1 sales and the addressable restorative market.

  3. Chapter 3

    The Competitive Landscape

    Profiles of Galderma, InMode, Apyx Medical, Evolus, Establishment Labs, and Conexeu Sciences, including approximate market capitalizations and positioning.

  4. Chapter 4

    Technology Differentiation

    Why neuromodulators and conventional biostimulators address different mechanisms than a temperature-responsive collagen-based scaffold designed for structural support.

  5. Chapter 5

    Near-Term Catalysts and Early Validation

    Targeted regulatory milestones, preclinical durability data, academic collaboration, and initial analyst coverage for the early-stage platform.

  6. Chapter 6

    Risks and the Cautionary Precedent

    Regulatory uncertainty, potential direct competition from GLP-1 manufacturers, capital intensity, valuation dispersion, and the Cutera Chapter 11 example.

  7. Chapter 7

    Framing Potential Exposure

    Considerations for core, value-with-controversy, and higher-volatility small-capitalization positions, presented as analytical frameworks rather than recommendations.

Meet the Authors

Marc X. LoPresti

Marc X. LoPresti

CEO & Chief Market Strategist
Market Rebellion

Read full bio

Marc LoPresti is Market Rebellion’s CEO and Chief Market Strategist. He’s a Wall Street veteran with over 25+ years of experience in alternative investments, having started his career on the floor of the NYSE working for Lehman Brothers.

Along with leading Market Rebellion, Marc was a recognized securities law and corporate finance attorney, venture capitalist, an experienced economist, and family office expert.

Marc appears regularly on CNN, Fox Business, NewsMax, NewsNation, CNBC, Sirius XM Radio, Bloomberg, and Reuters. He’s also been quoted in numerous publications including Forbes, the Wall Street Journal, Investor’s Business Daily, and Barron’s.

You can catch Marc LoPresti on numerous Market Rebellion broadcasts including Rebel’s Edge, Cocktail Hour, and weekly trading events.

Bill Johnson

Bill Johnson

Lead Instructor & Editor
Market Rebellion

Read full bio

Bill Johnson is Head of Education at Market Rebellion, where he specializes in teaching options and market strategy.

Previously, he worked with Active Trader Options at Charles Schwab, serving some of the firm’s most sophisticated and active traders.

Bill is the author of several books covering financial topics including options, single-stock futures, foreign exchange, and the Federal Reserve. He has also worked as a ghostwriter for publications and media outlets including Newsmax, Forbes, Fortune, Worth, and Heritage Auctions Magazine.

In academia, Bill served as an adjunct professor at Florida International University (FIU) in Miami, where he taught futures, options, and swaps. He was also a regular host on the 21st Century Alert radio show on WNN 1470 AM.

Bill earned a Master’s degree in Economics in 1996 and an MBA in Finance in 1999, both from University of Central Florida.

Have a question?

Our Sales Specialists are available to answer your questions.

8am – 6pm ET, Monday through Friday

Call us:

Call us to speak now with a member of our team.

+1 (888) 809-8058

Email us:

Have a question that you’d like our Sales Specialists to help you with?

[email protected]

Check out what members are saying:

What Customers are Saying

*Individual results may vary.

Trustpilot — TrustScore 4.6, 131 reviews

“Made my price to play in less than 30 days!”

— David

“Joined (3@3) on Sept 6 and have already made my investment back in Sept! “House Money” for 11 months :)”

— Al

“Let’s just say, if trading is your future: This is where you need to be!”

— Steven P.

“3@3 paid for itself in a couple of weeks for me. The Rebel Roundup Newsletter is worth the cost by itself! Many thanks.”

— Norbert

“I knew nothing about trading stocks and options. Since then I have learned a new life skill in trading and how to be safe doing so. Thank you for always looking out for us and trying to protect us.”

— Valentin M.

“(3@3) paid for itself in a few weeks.”

— Betty

“I have a lot of experience investing, having learned hard lessons throughout the years… Market Rebellion has made my life much easier and less stressful because of the increased consistency… Jon & Pete Najarian have, by far, the best investment services available.”

— Brent D.

“The level of in-depth trading education is far superior to anything else I have experienced.”

— Jack S.

“I have been with another 'option service' for 3 years. The Market Rebellion in-depth educational courses are much more advanced and informative.”

— Walter W.

“Market Rebellion's programs actually educate their students in options trading... From theory and strategies behind it, to technical analysis and understanding the markets as a whole... Their team of instructors and coaches have a depth of understanding, trading and market experience that is second to none. Before you spend a dime on any other kind of trading, portfolio and/or money management program, do yourself a favor and check out Market Rebellion first …”

— Shawn M.

Important Disclaimers

Market Rebellion

©2026 Market Rebellion, LLC. All Rights Reserved.